维奈克拉治疗慢性淋巴细胞白血病与急性髓系白血病的药物经济学再评价OA

OBJECTIVE:To systematically evaluate the pharmacoeconomic value of venetoclax(VEN)-based dual or triple combination regimens in the treatment of chronic lymphocytic leukemia(CLL)and acute myeloid leukemia(AML).METHODS:A systematic search of Chinese and English databases was conducted from the inception to May 2025 to identify pharmacoeconomic evaluations of VEN for hematological malignancies.The quality of the included studies was assessed using the CHEERS 2022 checklist.RESULTS:Twenty studies were included,all with CHEERS scores>80%.Key findings included that in terms of economic advantage,fourteen studies supported the cost-effectiveness of VEN-based regimens,with nine being dominant(more effective and less costly)and five demonstrating an incremental cost-effectiveness ratio(ICER)below local willingness-to-pay thresholds;in terms of contradictory findings,three studies indicated insufficient economic benefit,with Chinese research suggesting traditional regimens were more cost-effective;in terms of key influencing factors,long-term costs can be reduced by the fixed-duration treatment design,while the average monthly cost can be increased by tumor lysis syndrome(TLS)by USD 3 062;in terms of Chinese evidence,only two studies were from China,indicating VEN required a price reduction of approximately 60%to be cost-effective.CONCLUSIONS:VEN combination regimens are cost-effective in most healthcare systems,but their economic value is influenced by the healthcare structure,risk stratification,and costs associated with adverse events.High-quality specific pharmacoeconomic studies based on local parameters are urgently needed in China to support medical insurance decisions and individualized treatment.